FGF21 是一種主要在肝臟中產生的代謝激素。它通過多種組織中的多效作用調節葡萄糖和脂質代謝，並在各種壓力下防止代謝損傷。
 在人類中，高循環 FGF21 水平存在於肥胖和多種心臟代謝疾病中， 包括代謝綜合徵、2型糖尿病、非酒精性脂肪肝和冠狀動脈疾病。血清 FGF21 是這些疾病早期檢測和風險預測的潛在生物標誌物。

該測定是定量夾心ELISA。免疫板預先塗有對人 FGF-21 具有特異性的兔多克隆抗體。標準品和样品被吸入孔中，任何存在的人 FGF-21 都被固定的抗體結合。洗去任何未結合的物質後，將生物素標記的特異於人 FGF-21 的多克隆抗體添加到孔中。在去除任何未結合試劑的洗滌步驟後，加入鏈黴親和素-HRP 偶聯物 (STP-HRP)。在最後一個洗滌步驟後，加入 HRP 底物溶液，顏色與最初結合的人 FGF-21 的量成比例。 停止測定並使用酶標儀測定孔的光密度。由於吸光度的增加與捕獲的人 FGF-21 的量成正比，因此可以從每個分析中包含的參考曲線中插入未知樣品濃度。

一種。 標準曲線的典型代表

以下標準曲線僅供演示。應為每組樣品測定生成標準曲線。 

B. 敏感性

該測定法可檢測到的人 FGF-21 的最低水平為 30 皮克/毫升。

C. 特異性

重組蛋白的交叉反應

D. 精度

測定內精密度（測定內的精密度）

在一塊板上測試了兩個已知濃度的樣品 12 次。

測定間精度（測定之間的精度）

兩個已知濃度的樣品在 10 個單獨的測定中進行了測試。

E. 線性

為了評估測定的線性，含有和/或摻入高濃度人 FGF-21 的樣品用 1×測定緩衝液連續稀釋，以產生具有測定動態範圍內值的樣品。

示例 1

樣本 2

1. Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC, FIELD Study Investigators. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2012 Dec 1;97(12):4701-8.
2. Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, Jia W. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. Journal of hepatology. 2013 Mar 1;58(3):557-63.
3. Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PloS one. 2013 Oct 18;8(10):e78864.
4. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovascular diabetology. 2013 Dec;12(1):1-7.
5. Ong KL, Januszewski AS, O’Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar;58(3):464-73.
6. Zhang W, Chu S, Ding W, Wang F. Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One. 2015 Jun 19;10(6):e0129791.
7. Besseling J, Ong KL, Huijgen R, Rye KA, Hovingh GK, Hutten BA, Lambert G. The impact of LDLR function on fibroblast growth factor 21 levels. Atherosclerosis. 2015 Aug 1;241(2):322-5.
8. Ong KL, Januszewski AS, O’Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep;58(9):2035-44.
9. Chen DL, Liess C, Poljak A, Xu A, Zhang J, Thoma C, Trenell M, Milner B, Jenkins AB, Chisholm DJ, Samocha-Bonet D. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. The Journal of Clinical Endocrinology & Metabolism. 2015 Nov 1;100(11):4082-91.
10. Xiao Y, Liu L, Xu A, Zhou P, Long Z, Tu Y, Chen X, Tang W, Huang G, Zhou Z. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovascular diabetology. 2015 Dec;14(1):1-8.
11. Ye D, Li H, Wang Y, Jia W, Zhou J, Fan J, Man K, Lo C, Wong C, Wang Y, Lam KS. Circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia/reperfusion injury in patients with liver transplantation. Scientific reports. 2016 Jan 25;6(1):1-9.
12. Woo YC, Lee CH, Fong CH, Xu A, Tso AW, Cheung BM, Lam KS. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clinical endocrinology. 2017 Jan;86(1):37-43.
13. Chen DL, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins A, Chisholm D, Samocha-Bonet D, Macefield VG. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Frontiers in physiology. 2017 Feb 28;8:101.
14. Lee CH, Woo YC, Chow WS, Cheung CY, Fong CH, Yuen MM, Xu A, Tse HF, Lam KS. Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus. Journal of the American Heart Association. 2017 Jun 6;6(6):e005344.
15. Yang K, Deng HB, Man AW, Song E, Zhang J, Luo C, Cheung BM, Yuen KY, Jensen PS, Irmukhamedov A, Elie AG. Measuring non‐polyaminated lipocalin‐2 for cardiometabolic risk assessment. ESC heart failure. 2017 Nov;4(4):563-75.
16. Shen Y, Zhang X, Pan X, Xu Y, Xiong Q, Lu Z, Ma X, Bao Y, Jia W. Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death. Cardiovascular diabetology. 2017 Dec;16(1):1-7.
17. Shen Y, Zhang X, Xu Y, Xiong Q, Lu Z, Ma X, Bao Y, Jia W. Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease. Cardiology. 2018;139(4):212-8.
18. Li H, Wu G, Fang Q, Zhang M, Hui X, Sheng B, Wu L, Bao Y, Li P, Xu A, Jia W. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nature communications. 2018 Jan 18;9(1):1-6.
19. Hui TH, McClelland RL, Allison MA, Rodriguez CJ, Kronmal RA, Heckbert SR, Michos ED, Barter PJ, Rye KA, Ong KL. The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2018 Feb 1;269:86-91.
20. Liu JJ, Liu S, Choo RW, Wee SL, Xu A, Lim SC. Sex modulates the association of fibroblast growth factor 21 with end‐stage renal disease in Asian people with Type 2 diabetes: a 6.3‐year prospective cohort study. Diabetic Medicine. 2018 Jul;35(7):880-6.
21. Wong YK, Cheung CY, Tang CS, Au KW, Hai JS, Lee CH, Lau KK, Cheung BM, Sham PC, Xu A, Lam KS. Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2018 Oct;38(10):2519-27.
22. Hu Q, Wang C, Liu F, He J, Wang F, Wang W, You P. High serum levels of FGF21 are decreased in bipolar mania patients during psychotropic medication treatment and are associated with increased metabolism disturbance. Psychiatry research. 2019 Feb 1;272:643-8.
23. Ong KL, Hui N, Januszewski AS, Kaakoush NO, Xu A, Fayyad R, DeMicco DA, Jenkins AJ, Keech AC, Waters DD, Barter PJ. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism. 2019 Apr 1;93:93-9.
24. Tang A, Coster AC, Tonks KT, Heilbronn LK, Pocock N, Purtell L, Govendir M, Blythe J, Zhang J, Xu A, Chisholm DJ. Longitudinal changes in insulin resistance in normal weight, overweight and obese individuals. Journal of clinical medicine. 2019 May;8(5):623.
25. Anuwatmatee S, Allison MA, Shlipak MG, McClelland RL, Kramer H, Tang S, Hou L, Rye KA, Ong KL. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. Nephrology Dialysis Transplantation. 2019 Jun 1;34(6):1009-16.
26. Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long‐term nucleoside analogue. Liver International. 2019 Jul;39(7):1217-25.
27. Harari A, Coster AC, Jenkins A, Xu A, Greenfield JR, Harats D, Shaish A, Samocha-Bonet D. Obesity and insulin resistance are inversely associated with serum and adipose tissue carotenoid concentrations in adults. The Journal of nutrition. 2020 Jan 1;150(1):38-46.
28. Liu Y, Wang Y, Ni Y, Cheung CK, Lam KS, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell metabolism. 2020 Jan 7;31(1):77-91.
29.  

1. Tucker B, McClelland RL, Allison MA, Budoff MJ, Wu BJ, Barter PJ, Rye KA, Ong KL. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. Atherosclerosis. 2020 Apr 1;299:38-44.
2. Qian LL, Wu L, Zhang L, Zhang J, Zhou J, Li YH, Fang QC, Li HT, Jia WP. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. Acta Pharmacologica Sinica. 2020 Apr;41(4):554-60.
3. Lui DT, Lee CH, Chau VW, Fong CH, Yeung KM, Lam JK, Lee AC, Chow WS, Tan KC, Woo YC, Lam KS. Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance. Journal of Endocrinological Investigation. 2020 Jun 29:1-8.
4. Wu L, Qian L, Zhang L, Zhang J, Zhou J, Li Y, Hou X, Fang Q, Li H, Jia W. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. Journal of the American Heart Association. 2020 Jun 2;9(11):e015226.
5. Bishay RH, Tonks KT, George J, Samocha-Bonet D, Meyerowitz-Katz G, Chisholm DJ, James DE, Greenfield JR. Plasma bile acids more closely align with insulin resistance, visceral and hepatic adiposity than total adiposity. The Journal of Clinical Endocrinology & Metabolism. 2021 Mar;106(3):e1131-9.
6. Yang Y, Wu J, Wang X, Yao J, Lao KS, Qiao Y, Xu Y, Hu Y, Feng Y, Cui Y, Shi S. Circulating fibroblast growth factor 21 as a potential biomarker for missed abortion in humans. Fertility and Sterility. 2021 Jun 21.
7. Liu D, Wu L, Gao Q, Long X, Hou X, Qian L, Ni J, Fang Q, Li H, Jia W. FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China. Cardiovasc Diabetol. 2021 Jul 28;20(1):157.
8. Cheng F, Ng NY, Tam CH, Zhang Y, Lim CK, Jiang G, Ng AC, Yau TT, Cheung LP, Xu A, Chan JC. Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS. Endocrine connections. 2021 Oct 1;10(10):1243-52.
9. Liu D, Wu L, Gao Q, Long X, Hou X, Qian L, Ni J, Fang Q, Li H, Jia W. FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China. Cardiovascular diabetology. 2021 Dec;20(1):1-1.
10. Xie W, Li D, Shi Y, Yu N, Yan Y, Zhang Y, Yu Q, Li Y, Du J, Lin Z, Wu F. Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery. Front Cardiovasc Med. 2022 Apr 6;9:850517.
11. Lee CH, Lui DT, Cheung CY, Fong CH, Yuen MM, Woo YC, Chow WS, Wong IY, Xu A, Lam KS. Circulating AFABP, FGF21, and PEDF Levels as Prognostic Biomarkers of Sight-threatening Diabetic Retinopathy. J Clin Endocrinol Metab. 2023 Aug 18;108(9):e799-e806.
12. Qiu H, Song E, Hu Y, Li T, Ku KC, Wang C, Cheung BMY, Cheong LY, Wang Q, Wu X, Hoo RLC, Wang Y, Xu A. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis. Cell Mol Gastroenterol Hepatol. 2022;14(5):1003-1023.
13. Brzozowska MM, Isaacs M, Bliuc D, Baldock PA, Eisman JA, White CP, Greenfield JR, Center JR. Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period. Sci Rep. 2023 Apr 13;13(1):6032
14. Ni Y, Qian L, Siliceo SL, Long X, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia X, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G, Li H, Panagiotou G, Jia W. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metab. 2023 Sep 5;35(9):1530-1547.e8.